Advanz Pharma’s Ocaliva Drug Withdrawal: EU Court Upholds Revocation
Advanz Pharma’s liver disease drug Ocaliva (obeticholic acid) is no longer available in Europe. The General Court of the European Union upheld the European Commission’s decision to revoke its conditional marketing authorization (CMA).
Ocaliva received CMA in 2016, allowing its use for patients with primary biliary cholangitis (PBC) while more data was gathered. In June 2024, the European Medicines Agency (EMA) reviewed the drug’s safety and effectiveness and recommended the revocation of its CMA.
Advanz Pharma briefly suspended the EC’s decision while pursuing legal action but the General Court did not extend the suspension. This means Ocaliva is now withdrawn from all European Union member states and European Economic Area countries, including Iceland, Liechtenstein, and Norway. Advanz Pharma is still challenging the decision in court, with a ruling expected in 2025, but the revocation takes effect immediately.
The US Food and Drug Administration (FDA) has a similar position. The drug was fast-tracked for approval in 2016, but a black box warning was added two years later due to severe liver injury from improper dosing. Recently, the FDA denied full approval for the drug after its advisory committee found that the risks outweigh the benefits.
What are the potential alternatives to Ocaliva for patients with primary biliary cholangitis (PBC)?
Interview with Dr. Emily Johnson,Hepatologist and Expert on Liver Diseases
News Directory 3: Thank you for joining us today,Dr. Johnson.With the recent news that Advanz Pharma’s Ocaliva (obeticholic acid) has had it’s conditional marketing authorization revoked by the European Union, can you explain the implications for patients with primary biliary cholangitis (PBC)?
Dr. Emily johnson: Thank you for having me. The revocation of Ocaliva’s marketing authorization in the EU is quite significant, as it removes an crucial treatment option for patients suffering from PBC. This decision stems from the European Medicines Agency’s review in June 2024, which raised concerns about Ocaliva’s safety and efficacy based on available data. For patients, this means they will lose access to a medication that has been critical in managing their condition, notably for those who do not respond adequately to ursodeoxycholic acid (UDCA).
News Directory 3: Ocaliva was initially approved through a conditional marketing authorization. What dose that entail, and why was it significant for PBC patients at the time?
Dr. Johnson: Conditional marketing authorization allows a drug to be sold before all clinical data is fully finalized, provided that the company continues to gather further evidence to confirm safety and efficacy. This pathway was crucial in getting Ocaliva to patients quickly after its approval in 2016, as PBC is a rare and serious autoimmune disease that can lead to severe liver damage. patients needed options, and Ocaliva has been shown to help in managing bile acid levels and improving liver function in certain cases.
News Directory 3: This revocation seems to coincide with similar findings from the US FDA. How do the FDA’s recent actions regarding Ocaliva affect the landscape in the US?
Dr. Johnson: Yes, the FDA added a black box warning to ocaliva due to concerns about severe liver injuries and has recently denied full approval because the risks were deemed to outweigh the benefits. This puts healthcare providers in a challenging position, as they must weigh the risks of prescribing Ocaliva against its potential benefits. While it remains available under accelerated approval for Intercept Pharmaceuticals in the US, ongoing concerns could limit its use significantly.
News Directory 3: Advanz Pharma is currently challenging the EU’s revocation in court. What are the potential outcomes of such legal actions for patients?
Dr. Johnson: The court’s ruling could lead to a few outcomes. If they rule in favor of Advanz, there might be a reinstatement of Ocaliva’s authorization while further data is evaluated. However, if the revocation stands, it could leave patients in Europe without an important treatment option until potentially new evidence is brought forth, which could take considerable time. For now, it raises questions about treatment continuity for those relying on Ocaliva.
News Directory 3: Can you elaborate on the therapeutic role of Ocaliva for PBC patients and what alternatives they might consider moving forward?
Dr. Johnson: Ocaliva, as an FXR agonist, plays a vital role in bile acid management, which is crucial for the health of the liver in PBC patients. For patients who cannot take UDCA or do not respond adequately, Ocaliva has been a key therapy. Moving forward, patients may need to rely more heavily on UDCA or participate in clinical trials for other emerging therapies aimed at treating PBC. It underscores the importance of ongoing research in this area.
News Directory 3: Thank you, Dr. johnson, for your insights into this pressing issue affecting PBC patients.
Dr. Johnson: Thank you for shining a light on this important topic. It’s vital for patients to stay informed and involved in discussions about their treatment options.
Advanz Pharma acquired the drug’s rights in Europe from Intercept Pharmaceuticals in 2022 for $405 million. Intercept still holds the US rights and says Ocaliva will remain available there under accelerated approval, as it discusses the next steps with the FDA.
Primary biliary cholangitis is a rare autoimmune disease that harms the liver’s bile ducts. Ocaliva works as a farnesoid X receptor (FXR) agonist that helps manage bile acid and metabolic processes, improving patient outcomes. It is prescribed with ursodeoxycholic acid (UDCA) for patients with insufficient responses or as a standalone treatment for those who cannot take UDCA.